CHIEF EXECUTIVE OFFICER

Mr. Murphy is an experienced business executive and international lawyer. He sits on numerous company boards and is the Founding Partner of Murphy & Company LLP, a leading business law firm in Vancouver, Canada. Prior to founding Murphy & Company, he practised law with a prominent national law firm in Calgary, Alberta, gained international experience as an associate in the finance law group of a British “magic circle” law firm and served as in-house legal counsel for a multinational software company in Paris, France. Mr. Murphy holds a bachelor of laws (LL.B) degree from the University of Saskatchewan, a master of laws (LL.M) degree from McGill University and is a member of the law societies of British Columbia and England & Wales.

CHIEF BUSINESS DEVELOPMENT OFFICER & DIRECTOR

Dr. Saad has an extensive track record in strategic planning and implementing significant projects, ability to define goals and delivering results. As Head of BD at Aspreva Pharmaceuticals, she produced licensing strategies, and led >60 due diligences and negotiations of potential M&As of a cumulative value exceeding $8bln. She won the 2006 Aspreva Leadership Award for being a role model of leadership and an excellent example of High Impact both through her words and actions.

Most recently Dr. Saad was Green Sky Labs’ CBO, and CEO of the pharmaceutical Division. She led teams that effectively isolated cannabinoids, initiated 3 clinical trials, and compiled a comprehensive database linking medical conditions to cannabinoid treatments.

Dr. Saad was an inventor/co-inventor of two patents during her tenure at MedBiogene. She holds a PhD in Microbiology (McGill University) and an MBA (University of Montreal).

DIRECTOR

Dr. Haney is an experienced scientist and research coordinator who has managed a range of research projects and teams of up to 20 people over the past 10 years. He is an inventor of various technologies addressing the issue of antibiotic resistance and antibiotic failure and has in-depth experience with various activities relevant to clinical research and technology innovation. He has published over 50 papers in scientific journals, including two major reviews in Nature journals related to peptide optimization and their development as therapeutics, particularly as antibiofilm agents. Dr. Haney holds a Ph.D. in Biochemistry from the University of Calgary.